Down-regulation of CD81 tetraspanin in human cells producing retroviral-based particles: Tailoring vector composition

Biotechnology and Bioengineering

Volumn 108, Issue 11, 2011, Pages 2623-2633

  Rodrigues, A F ^a,b   Guerreiro, M R ^a,b   Santiago, V M ^a   Dalba, C ^c   Klatzmann, D ^d   Alves, P M ^a,b   Carrondo, M J T ^a,b,e   Coroadinha, A S ^a,b  

^a INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLÓGICA   (Portugal)

^b INSTITUTO DE TECNOLOGIA QUÍMICA E BIOLÓGICA   (Portugal)

^c EPIXIS SA   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

CD81; Host proteins; Immunotoxicity; Retroviral vector; Retrovirus like particles; ShRNA; Vaccines and gene therapy

Indexed keywords

CD81; HOST PROTEINS; IMMUNOTOXICITY; RETROVIRAL VECTORS; RETROVIRUS-LIKE PARTICLES; SHRNA;

CELL PROLIFERATION; CLONE CELLS; GENE THERAPY; GENETIC ENGINEERING; MAMMALS; PRODUCTIVITY; PROTEINS; RNA; VIRUSES;

VECTORS;

CD81 ANTIGEN; LENTIVIRUS VECTOR; RETROVIRUS VECTOR; SHORT HAIRPIN RNA; TETRASPANIN;

ANTIGEN EXPRESSION; ARTICLE; CELL PROLIFERATION; DOWN REGULATION; GENE SILENCING; GENE THERAPY; GENETIC TRANSDUCTION; HALF LIFE TIME; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTOXICITY; NONHUMAN; OXIDATIVE STRESS; PHARMACODYNAMICS; PROTEIN CONTENT; RNA INTERFERENCE; VIRUS ENVELOPE; VIRUS LIKE AGENT; VIRUS PARTICLE;

ANIMALS; ANTIGENS, CD81; BIOLOGICAL AGENTS; CELL LINE; DOWN-REGULATION; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; GENETIC VECTORS; HUMANS; MICE; RETROVIRIDAE;

MUS;

EID: 80053052764     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.23231     Document Type: Article

References (34)

1. Arthur LO, Bess JW, Jr, Urban RG, Strominger JL, Morton WR, Mann DL, Henderson LE, Benveniste RE. 1995. Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus. J Virol 69(5): 3117-3124.
2. Bellier B, Dalba C, Clerc B, Desjardins D, Drury R, Cosset FL, Collins M, Klatzmann D. 2006. DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant. Vaccine 24(14): 2643-2655.
3. Bellier B, Huret C, Miyalou M, Desjardins D, Frenkiel MP, Despres P, Tangy F, Dalba C, Klatzmann D. 2009. DNA vaccines expressing retrovirus-like particles are efficient immunogens to induce neutralizing antibodies. Vaccine 27(42): 5772-5780.
4. Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, Iggo R. 2003. Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 34(3): 263-264.
5. Coroadinha AS, Schucht R, Gama-Norton L, Wirth D, Hauser H, Carrondo MJ. 2006a. The use of recombinase mediated cassette exchange in retroviral vector producer cell lines: Predictability and efficiency by transgene exchange. J Biotechnol 124(2): 457-468.
6. Coroadinha AS, Silva AC, Pires E, Coelho A, Alves PM, Carrondo MJ. 2006b. Effect of osmotic pressure on the production of retroviral vectors: Enhancement in vector stability. Biotechnol Bioeng 94(2): 322-329.
7. Cosset FL, Takeuchi Y, Battini JL, Weiss RA, Collins MK. 1995. High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 69(12): 7430-7436.
8. Crotta S, Ronconi V, Ulivieri C, Baldari CT, Valiante NM, Abrignani S, Wack A. 2006. Cytoskeleton rearrangement induced by tetraspanin engagement modulates the activation of T and NK cells. Eur J Immunol 36(4): 919-929.
9. Dalba C, Bellier B, Kasahara N, Klatzmann D. 2007. Replication-competent vectors and empty virus-like particles: New retroviral vector designs for cancer gene therapy or vaccines. Mol Ther 15(3): 457-466.
10. Dalba C, Klatzmann D, Logg CR, Kasahara N. 2005. Beyond oncolytic virotherapy: Replication-competent retrovirus vectors for selective and stable transduction of tumors. Curr Gene Ther 5(6): 655-667.
11. Danos O, Mulligan RC. 1988. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci USA 85(17): 6460-6464.
12. Dumay-Odelot H, Durrieu-Gaillard S, Da Silva D, Roeder RG, Teichmann M. 2010. Cell growth- and differentiation-dependent regulation of RNA polymerase III transcription. Cell Cycle 9(18): 3687-3699.
13. Edelstein ML, Abedi MR, Wixon J. 2007. Gene therapy clinical trials worldwide to 2007-An update. J Gene Med 9(10): 833-842.
14. Editorial. 2003. Whither RNAi? Nat Cell Biol 5(6): 489-490.
15. Fish RJ, Kruithof EK. 2004. Short-term cytotoxic effects and long-term instability of RNAi delivered using lentiviral vectors. BMC Mol Biol 5: 9.
16. Geisert EE, Jr, Abel HJ, Fan L, Geisert GR. 2002. Retinal pigment epithelium of the rat express CD81, the target of the anti-proliferative antibody (TAPA). Invest Ophthalmol Vis Sci 43(1): 274-280.
17. Geisert EE, Jr, Yang L, Irwin MH. 1996. Astrocyte growth, reactivity, and the target of the antiproliferative antibody, TAPA. J Neurosci 16(17): 5478-5487.
18. Gladnikoff M, Shimoni E, Gov NS, Rousso I. 2009. Retroviral assembly and budding occur through an actin-driven mechanism. Biophys J 97(9): 2419-2428.
19. Hammarstedt M, Wallengren K, Pedersen KW, Roos N, Garoff H. 2000. Minimal exclusion of plasma membrane proteins during retroviral envelope formation. Proc Natl Acad Sci USA 97(13): 7527-7532.
20. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet G, Linsley PS. 2003. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 21(6): 635-637.
21. Kaufman RJ. 1999. Double-stranded RNA-activated protein kinase mediates virus-induced apoptosis: A new role for an old actor. Proc Natl Acad Sci USA 96(21): 11693-11695.
22. Levy S, Todd SC, Maecker HT. 1998. CD81 (TAPA-1): A molecule involved in signal transduction and cell adhesion in the immune system. Annu Rev Immunol 16: 89-109.
23. Maecker HT, Todd SC, Levy S. 1997. The tetraspanin superfamily: Molecular facilitators. Faseb J 11(6): 428-442.
24. Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G, Piqani B, Eisenhaure TM, Luo B, Grenier JK, Carpenter AE, Foo SY, Stewart SA, Stockwell BR, Hacohen N, Hahn WC, Lander ES, Sabatini DM, Root DE. 2006. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124(6): 1283-1298.
25. Naghavi MH, Goff SP. 2007. Retroviral proteins that interact with the host cell cytoskeleton. Curr Opin Immunol 19(4): 402-407.
26. Oren R, Takahashi S, Doss C, Levy R, Levy S. 1990. TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins. Mol Cell Biol 10(8): 4007-4015.
27. Ott DE. 1997. Cellular proteins in HIV virions. Rev Med Virol 7(3): 167-180.
28. Ott DE. 2002. Potential roles of cellular proteins in HIV-1. Rev Med Virol 12(6): 359-374.
29. Penas PF, Garcia-Diez A, Sanchez-Madrid F, Yanez-Mo M. 2000. Tetraspanins are localized at motility-related structures and involved in normal human keratinocyte wound healing migration. J Invest Dermatol 114(6): 1126-1135.
30. Rodrigues AF, Carmo M, Alves PM, Coroadinha AS. 2009. Retroviral vector production under serum deprivation: The role of lipids. Biotechnol Bioeng 104(6): 1171-1181.
31. Scacheri PC, Rozenblatt-Rosen O, Caplen NJ, Wolfsberg TG, Umayam L, Lee JC, Hughes CM, Shanmugam KS, Bhattacharjee A, Meyerson M, Collins FS, 2004. Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc Natl Acad Sci USA 101(7): 1892-1897.
32. Segura MM, Garnier A, Di Falco MR, Whissell G, Meneses-Acosta A, Arcand N, Kamen A. 2008. Identification of host proteins associated with retroviral vector particles by proteomic analysis of highly purified vector preparations. J Virol 82(3): 1107-1117.
33. Shan G. 2010. RNA interference as a gene knockdown technique. Int J Biochem Cell Biol MicroRNAs Dev Dis 42(8): 1243-1251.
34. Toledo MS, Suzuki E, Handa K, Hakomori S. 2004. Cell growth regulation through GM3-enriched microdomain (glycosynapse) in human lung embryonal fibroblast WI38 and its oncogenic transformant VA13. J Biol Chem 279(33): 34655-34664.